Frederick, MD., Aug. 14, 2024 -- Veralox Therapeutics, a clinical-stage biotechnology company developing first-in-class therapies targeting the 12-lipoxygenase (12-LOX) pathway, announced that the European Medicines Agency (EMA) has granted Orphan...
Wake Forest University School of Medicine Develops Digital Platform to Better Care for Stroke Patients
August 9, 2022: Pappas managed Catalyst Fund provides funding to develop Wake Forest University School of Medicine digital platform.
